Anti-Human CD86
Anti-Human CD86
Product No.: B567
- -
- -
Clone 37301 Target CD86 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names B7-2, B70, Ly-58, CD-86 Isotype IgG1 Applications CyTOF® , FC , N , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen Purified Recombinant Human B7-2 (>98%) (Accession # P42081) Formulation This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present. Storage and Handling The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months. Country of Origin USA Shipping Next Day Ambient RRIDAB_2828239 Applications and Recommended Usage? Quality Tested by Leinco Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing B7-2. A suggested method would be to stain cells expressing B7-2 with 0.25 µg per 1-2.5 x 106 cells in a total staining volume of ≤200 µl followed by PN:M1189. Western Blotting: To detect Human B7-2 this monoclonal antibody can be used at a concentration of 5 µg/ml. This monoclonal antibody should be used in conjunction with compatible second-step reagents such as PN:M114 and a chromogenic substrate such as PN:T343. The detection limit for Human B7-2 is 10 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:B533. Additional Applications Reported In Literature ? Neutralization: This antibody is useful for neutralization of Human B7-2 bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human B7-2 (at 10 ng/ml) is 0.005 - 0.01 µg/ml. CyTOF-ready: Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 37301 recognizes an epitope on human CD86. Background CD86 is an 80kD Ig superfamily member that is involved in immunoglobulin class-switching and activation of NK cell-mediated cytotoxicity. CD80 is closely related to, and works in tandem with CD86 to prime T- cells. CD86 is expressed earlier in the immune response than CD80. The ligation of CD28 on T cells with CD80 and CD86 on APCs co-stimulates T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD86 can also bind to CTLA-4 to deliver an inhibitory signal to T cells. Antigen Distribution CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. PubMed References & CitationsTechnical ProtocolsCertificate of Analysis |
Formats Available
